drugset

drugset / Trial / NCT02529553

A Study of LY3076226 in Participants With Advanced or Metastatic Cancer

NCT02529553 ↗

Phase 1 Completed 25 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3076226 in participants with advanced or metastatic cancer.

Timeline

Start: 2015-09
Primary completion: 2018-03-28
Completion: 2018-03-28

Publications

Kollmannsberger C, Britten CD, Olszanski AJ, Walker JA, Zang W, Willard MD, Radtke DB, Farrington DL, Bell-McGuinn KM, Patnaik A. A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. Invest New Drugs. 2021 Dec;39(6):1613-1623. doi: 10.1007/s10637-021-01146-x. Epub 2021 Jul 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3076226	Monoclonal antibody	—	Intravenous

Indications